Balyasny Asset Management
XERS icon

Balyasny Asset Management’s Xeris Biopharma Holdings XERS Stock Holding History

Balyasny Asset Management’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-34,454
Closed -$189K – 3435
2025
Q1 		$189K Buy
34,454
+17,301
+101% +$69.8K ﹤0.01% 2598
2024
Q4 		$58.1K Buy
+17,153
New +$55.2K ﹤0.01% 2631
2022
Q2 		– Sell
-109,305
Closed -$280K – 3246
2022
Q1 		$280K Buy
109,305
+89,877
+463% +$220K ﹤0.01% 1944
2021
Q4 		$57K Buy
+19,428
New +$42K ﹤0.01% 2047

Other funds holding XERS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Balyasny Asset Management's XERS Position: Q2 2025 in Review

Balyasny Asset Management sold out of Xeris Biopharma Holdings (XERS) in Q2 2025, closing a stake of 34,454 shares — an estimated $189K sold.

Balyasny Asset Management first reported a position in XERS in Q4 2021 and held it in 4 quarters. The position peaked at $280K in Q1 2022. 200 funds tracked by Wall St. Rank hold XERS as of Q2 2025.

  • Balyasny Asset Management reported no remaining Xeris Biopharma Holdings position as of Q2 2025 after selling out during the quarter.
  • Balyasny Asset Management sold 34,454 Xeris Biopharma Holdings shares in Q2 2025, an estimated $189K.
  • Balyasny Asset Management first reported a position in Xeris Biopharma Holdings in Q4 2021 and held it in 4 quarters.
  • Balyasny Asset Management's Xeris Biopharma Holdings position peaked at $280K in Q1 2022.
  • 200 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2025.

Based on Balyasny Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.